Global Antibody Drug Conjugate (ADC) Competitive Landscape Report 2023: Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs
November 17, 2023 08:13 ET
|
Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Global CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of Therapies
November 09, 2023 05:58 ET
|
Research and Markets
Dublin, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The "Global CD19 Antibody Market & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The global CD19...
Global CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in Immunotherapy
November 03, 2023 07:43 ET
|
Research and Markets
Dublin, Nov. 03, 2023 (GLOBE NEWSWIRE) -- The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The global CD19 Antibody...
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023 16:05 ET
|
Prelude Therapeutics, Inc.; AbCellera
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Global Antibody Drug Conjugates Market Poised to Reach $19.8 Billion by 2028, Fueled by Increasing Cancer Prevalence and Clinical Advancements
October 26, 2023 07:33 ET
|
Research and Markets
Dublin, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type...
Elucida Oncology Presents Encouraging Clinical Data from Phase 1/2 Study of ELU001 in Solid Tumors Overexpressing Folate Receptor Alpha at ESMO Congress 2023
October 23, 2023 08:00 ET
|
Elucida Oncology, Inc
Anti-tumor activity observed across all levels of folate receptor alpha (“FRα”) expression89% of patients with cancers expressing FRα showed stable disease or a partial response following treatment...
ADC (Antibody Drug Conjugates) Markets, 2035
October 17, 2023 07:38 ET
|
Research and Markets
Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) - Distribution by Generation of ADC Technology, Type of...
Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners
October 09, 2023 08:04 ET
|
The Insight Partners
Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently...
Antibody Drug Conjugates Market to increase by USD 34.7 Billion by 2032 || North America led with a 40% revenue share in 2022
September 25, 2023 09:23 ET
|
Market.Us
New York, Sept. 25, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Market.us, the Global Antibody Drug Conjugates Market size is expected to be worth around USD 34.7 Billion by 2032 from...
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
August 24, 2023 11:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...